Berlin-based Cantourage provides Fast Track Access to the European medical cannabis market for international cultivators


Ryan Allway

June 16th, 2021

News


– European cannabis company Cantourage launches a new platform enabling cannabis cultivators from across the world to enter the EU/UK market swiftly and reliably.

– Cantourage guarantees compliance to highest European quality standards for all products on its platform and developed and implemented new energy-efficient and gentle production methods which lead to high-quality flower products – first product is already available in German pharmacies: Cannabis Flos FOTMER T3h.

– Cantourage has closed its Series B funding with a high double-digit million-euro valuation.

 

 

BERLINJune 16, 2021 /CNW/ — European medical cannabis company Cantourage today launched its new and innovative platform, enabling cultivators from across the world to bring their product into the growing and profitable European market more quickly and cheaply. Already a price leader with a significant market share in the competitive German Dronabinol market, Cantourage and its partners now offer products in all relevant market segments – dried flowers, extracts and Dronabinol.

 

“We look forward to expanding our offering with the launch of our platform, which kicks off with more than 10 partners from all continents. The current European market is dominated by just a few companies. Market entrants face many hurdles when trying to enter these profitable markets. We empower cultivators and offer them fast-tracked, secure European market access, while helping them grow their brand”, Philip Schetter, Co-CEO of Cantourage, comments. “Our platform expands and enhances the offering to patients and healthcare providers in Europe, in terms of both product and pricing. More importantly, Cantourage guarantees the highest European quality standards for flowers from all over the world. We are set to revolutionize the market”, Dr. Florian Holzapfel, Co-founder of Cantourage, added.

 

Cantourage disrupts and breaks the current market oligopoly by offering unbureaucratic and fast market access to the European market to cannabis cultivators worldwide. The company enables cultivators to sell under their own brands. Through its presence in various segments, Cantourage aims to democratize the market, offer pharmacies and medical cannabis distributors alternative buying opportunities across the entire market offering, and create new opportunities for the market to further grow. Based in Germany but already active across Europe in four countries, Cantourage is set-up to scale at high speed.

 

Norman Ruchholtz, Co-CEO at Cantourage says: “The European market for medical cannabis is the fastest-growing, with over 20 European countries already having legalized medical cannabis and sales expected to generate over $3 billion by 2025. Roughly 1 – 2% of the population is estimated to be a potential medical cannabis patient, but access to the European market for producers and the offering for patients is still highly restricted, with just a few players creating a quasi-oligopoly. We firmly believe – in the interest of our customers – that this market is ripe for change and disruption.”

 

More than 10 cultivators from all continents, from Jamaica through to Portugal and Uruguay, have already signed on as partners and clients, with more scheduled to join in a few weeks’ time. “Cantourage is one of the few players that can supply the market at high speed – leveraging its existing production and distribution networks. Our dried flower product Flos FOTMER T3h is already available in German pharmacies. Together with our investors, we will further grow our European footprint and reach to service additional markets,” explains Co-founder Patrick Hoffmann.

 

Recently, the already profitable company closed its Series B funding, led by long-term partner Think.Health Ventures. Next to all previous investors, 10x Group joined the funding round which was set at a high double-digit million Euro valuation.

 

“The management team leading Cantourage is exceptional. Their 25-plus years of experience, deep understanding of the market, exceptional set-up and aim of expanding the offerings in the market makes us very excited to be on board.” explains Dr. Florian Kainzinger, CEO of Think.Health Ventures, which was also the first venture capital firm in 2015 to invest in the medical cannabis sector in Germany.

 

Cantourage with its market disrupting model and the more than 10 signed supply contracts in place, is about to become one of the European leaders in medical cannabis.

 

About Cantourage

Cantourage is a leading European medical cannabis company. The Berlin-based company was founded in 2019 by industry pioneers Dr. Florian Holzapfel, Norman Ruchholtz and Patrick Hoffman. Cantourage enables producers from across the world to bring their product into the growing and profitable European market more quickly and cheaply, while guaranteeing and further developing highest European quality standards. It offers products in all relevant market segments: dried flowers, extracts and Dronabinol, with a strong and growing market share in the latter.

 

Press contact
Kekst CNC
[email protected]
Roland Leithaeuser
+49 162-207-4592

SOURCE Cantourage

 

 

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading